NUFORMIX PLC

Board/Management Information • Feb 1, 2022

National Storage Mechanism | Additional information

RNS Number : 2273A

Nuformix PLC

01 February 2022

1 February 2022

Nuformix plc

("Nuformix" or the "Company")

Adviser Appointments

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Stanford Capital Partners Limited as Financial Adviser and Broker to the Company, with immediate effect. 

Additionally, IFC Advisory Limited have been appointed as the Company's new financial public relations and investor relations adviser with immediate effect.

Enquiries:

Nuformix plc
Dr Alastair Riddell, Executive Chairman	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	+44 (0) 20 3650 3650
John Howes (Corporate Broking)	+44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6630

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase I-ready assets with potential for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPBKDBBCBKDQDN